WNT5A encodes a member of the Wnt family of secreted signaling proteins that operates primarily through non-canonical (β-catenin-independent) pathways. Inside the pancreas, Wnt5a acts as a direct regulator of insulin secretion; in adipose tissue, the same molecule becomes a pro-inflammatory driver when its natural brake — the adipokine SFRP5 — is lost. A common variant near this gene on chromosome 3p14 alters its regulatory landscape and shifts type 2 diabetes risk in the population.

The Mechanism

rs358806 sits within a long non-coding RNA (LINC02030) approximately 186 kilobases upstream of the WNT5A transcription start site. This positions it in the regulatory hinterland ¹¹ Cis-regulatory elements at this distance are routinely associated with gene expression changes in tissue-specific contexts, including pancreatic islets and adipocytes that controls when and how strongly WNT5A is expressed.

In pancreatic beta cells, Wnt5a promotes insulin secretion through a two-stage signaling cascade: it activates the Wnt-calcium pathway, raising intracellular Ca²⁺ and phosphorylating CamKII²² CamKII
Calcium/calmodulin-dependent protein kinase II — a key sensor of calcium signals in beta cells, which in turn up-regulates FoxO1, PDX-1, and GLUT2. These transcription factors are essential for glucose-stimulated insulin secretion. Wnt5a concentrations are reduced in patients with established type 2 diabetes, and GLP-1 receptor agonist treatment that raises serum Wnt5a correlates directly with improved beta-cell function as measured by HOMA-β³³ GLP-1 receptor agonist treatment that raises serum Wnt5a correlates directly with improved beta-cell function as measured by HOMA-β
Xu et al. 2023, PMID 37255814.

In adipose tissue, Wnt5a plays a different role. SFRP5, an anti-inflammatory adipokine secreted by healthy fat cells, normally restrains Wnt5a signaling. When SFRP5 production falls in obesity, uncontrolled Wnt5a activates the JNK pathway, driving macrophage infiltration into adipose tissue and causing glucose intolerance and hepatic steatosis in mouse models. This Science paper⁴⁴ This Science paper
Ouchi et al. Sfrp5 is an anti-inflammatory adipokine that ameliorates metabolic syndrome. Science, 2010 showed that delivering SFRP5 to obese mice reversed both phenotypes, identifying excess Wnt5a signaling as a causal driver of metabolic dysfunction.

The Evidence

The genetic association was first documented in the landmark WTCCC genome-wide association study⁵⁵ WTCCC genome-wide association study
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, which genotyped ~500,000 variants in ~2,000 cases each of bipolar disorder, coronary artery disease, Crohn's disease, rheumatoid arthritis, hypertension, type 1 and type 2 diabetes. rs358806 reached p = 3×10⁻⁶ for type 2 diabetes with an overall OR of 1.16 (95% CI 1.03–1.33). SNPedia genotype analysis places the CC homozygous risk at 1.78-fold relative to the AA reference genotype.

The C allele is the major allele globally (~80%), meaning most people carry at least one copy and about 64% are CC homozygotes. This positions rs358806 as a common, modest-effect risk variant — classically the type most relevant to population-level T2D burden rather than rare high-penetrance disease.

Practical Actions

For CC homozygotes, the key intervention is supporting the insulin secretion pathway that Wnt5a facilitates. Dietary patterns that reduce beta-cell burden — emphasising low-glycaemic foods, adequate protein, and limiting refined carbohydrates — preserve residual secretory capacity. Because Wnt5a in adipose tissue also interfaces with inflammation through the SFRP5 pathway, limiting visceral fat accumulation (particularly through reducing refined carbohydrate and fructose intake) is specifically relevant. Monitoring fasting glucose and HbA1c allows early intervention before beta-cell function deteriorates.

Interactions

TCF7L2 (rs7903146) and this variant act on overlapping pathways — both affect Wnt signalling and beta-cell function. Individuals who carry risk alleles at both loci face a compounded impairment of insulin secretory capacity. The FTO obesity variant (rs9939609) adds an independent adiposity component that can worsen the SFRP5/Wnt5a adipose inflammatory axis. WNT5A also interacts with PPARG-related variants (rs1801282) in the adipocyte differentiation pathway, since WNT5A is a positive regulator of adipogenesis via non-canonical signalling.

AKT1 (also called protein kinase B, or PKB) is a master regulator sitting at the center of the insulin and IGF-1 signaling cascade — the most evolutionarily conserved longevity pathway known, from roundworms to humans. When insulin or IGF-1 binds its receptor, PI3K activates and recruits AKT1 to the cell membrane, where it is phosphorylated and switches on. From there, activated AKT1 reaches into nearly every aspect of cell survival, growth, and metabolism: it phosphorylates and inactivates FOXO3 (suppressing the stress-resistance transcription factor), activates mTOR (accelerating protein synthesis and suppressing autophagy), and regulates glucose uptake, apoptosis, and inflammatory signaling. The conserved nature of this pathway is remarkable¹¹ The conserved nature of this pathway is remarkable
Kenyon CJ. The genetics of ageing. Nature, 2010 — reducing insulin/IGF-1 signaling extends lifespan across every organism where this has been tested, from yeast to worms to flies to mice.

rs3803304 sits in intron 9 of AKT1, approximately 70 base pairs upstream of a conserved exon-intron boundary, in a region of high predicted regulatory potential that also contains a CpG island. Although intronic, it is not merely a passive passenger variant: cells bearing the minor G allele exhibit measurably elevated levels of phosphorylated AKT protein in both resting and stimulated conditions, suggesting the variant modulates AKT activation capacity rather than AKT expression alone. The proposed mechanism involves disruption of an RNA regulatory element at the nearby splice boundary, potentially affecting alternative splicing or transcript stability of specific AKT1 isoforms.

The Mechanism

AKT1's role in longevity operates through a central tension in cell biology: growth versus maintenance. Chronically elevated AKT activity drives mTORC1 phosphorylation of S6K1 and 4E-BP1 to push protein synthesis, cell growth, and proliferation — all beneficial in youth, but increasingly detrimental with age as they suppress autophagy (the cellular cleanup system), promote inflammatory signaling, and accelerate cellular senescence. Conversely, reducing AKT/mTOR activity below the threshold needed for unrestricted growth shifts cells toward the housekeeping functions that protect against aging²² reducing AKT/mTOR activity below the threshold needed for unrestricted growth shifts cells toward the housekeeping functions that protect against aging
Kenyon C. The genetics of ageing. Nature, 2010.

The G allele at rs3803304 appears to modestly increase AKT phosphorylation capacity, nudging the signaling axis toward higher chronic AKT activity. For AKT1's downstream targets, this translates to: increased phospho-FOXO3 (keeping the longevity transcription factor cytoplasmic and inactive), higher mTORC1 throughput (suppressing autophagy), and elevated inflammatory NF-kB signaling. Over decades, these small shifts compound into meaningful differences in cancer risk, cardiovascular aging, and overall lifespan.

The Evidence

The key longevity findings come from a systematic screen of 291 common variants across 30 insulin/IGF1 pathway genes. Pawlikowska et al. (2009)³³ Pawlikowska et al. (2009)
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell, 2009 genotyped three independent Caucasian cohorts: the Study of Osteoporotic Fractures (293 cases ≥92 years / 603 controls ≤79 years), the Cardiovascular Health Study, and Ashkenazi Jewish Centenarians. rs3803304 emerged as the top AKT1 signal, with homozygous GG individuals markedly underrepresented among long-lived cases (recessive model OR=0.41–0.50 across cohorts, unadjusted p=0.0004; per-allele OR=0.78, permutation-adjusted p=0.043). The effect followed a recessive pattern — single G-allele carriers showed no significant longevity disadvantage (p=0.12), but GG homozygotes were consistently depleted among centenarians across three independent populations.

The biological interpretation was strengthened by a subsequent functional study. Crezee et al. (2020)⁴⁴ Crezee et al. (2020)
Akt1 genetic variants confer increased susceptibility to thyroid cancer. Endocrine Connections, 2020 confirmed that carriers of the minor allele at rs3803304 — reported in coding-strand notation in that paper but corresponding to the G allele on the plus strand — exhibit elevated levels of phosphorylated AKT protein in both unstimulated and stimulated conditions. The same allele conferred OR=1.587 for non-medullary thyroid cancer in two independent European cohorts (Dutch: 154 cases / 188 controls; Romanian: 159 cases / 260 controls). Elevated AKT phosphorylation capacity provides a coherent biological link between this intronic variant and both cancer risk and reduced longevity probability: more active AKT means more suppressed FOXO3, more mTORC1 activity, and more proliferative cellular drive.

[A sex-stratified age-at-death analysis | TenNapel MJ et al. SIRT6 Minor Allele Genotype Is Associated with

5-Year Decrease in Lifespan in an Aged Cohort. PLOS One, 2014](https://pubmed.ncbi.nlm.nih.gov/25541994/⁵⁵ https://pubmed.ncbi.nlm.nih.gov/25541994/) found a significant gender interaction (p=0.04): CC women lived on average 2.2 years longer than GG women and 1.8 years longer than CG women, while males showed a modest opposite pattern. The sex-specificity aligns with the fact that the initial longevity discovery cohort (SOF) was exclusively female, and estrogen signaling is known to modulate AKT1 activity and downstream FOXO biology differently by sex.

The picture is incomplete: an independent replication by Nygaard et al. (2013)⁶⁶ Nygaard et al. (2013)
AKT1 fails to replicate as a longevity-associated gene in Danish and German nonagenarians and centenarians. Eur J Hum Genet, 2013 found no significant associations in 2,996 long-lived individuals and 1,840 controls, and a Han Chinese study Li et al. (2016)⁷⁷ Li et al. (2016)
Association study of polymorphisms in FOXO3, AKT1 and IGF-2R genes with human longevity in a Han Chinese population. Oncotarget, 2016 found no association either. The evidence remains moderate: consistent functional biology, initial multi-cohort discovery, plausible mechanism, but inconsistent replication across populations and likely population- and sex-specific effects.

Practical Actions

For GG homozygotes, the actionable implication centers on managing the consequences of elevated chronic AKT1 signaling. Since AKT activates mTORC1 and suppresses FOXO3 and autophagy, the most evidence-based counterstrategies are interventions that independently suppress mTOR and restore FOXO3 activity: periodic fasting or caloric restriction (which reduces insulin/IGF-1 levels and thus upstream AKT activation), protein cycling rather than continuous high-protein intake (BCAA/leucine drive mTOR independently of AKT), and resistance training (which paradoxically improves insulin sensitivity and normalizes the AKT signaling response over time).

GG individuals may also benefit from more proactive cancer surveillance given the thyroid cancer risk association, and from monitoring fasting insulin and IGF-1 levels as biomarkers of AKT pathway activity. Fasting insulin above 5–7 mIU/L at rest signals chronically elevated upstream signaling that would further amplify the variant's effect.

Interactions

rs3803304 operates squarely within the same longevity signaling network as FOXO3A rs2802292 and MTOR rs2295080. AKT1 phosphorylates and inactivates FOXO3 — so GG carriers at rs3803304 (elevated AKT activity) would be expected to show blunted FOXO3 signaling, potentially negating the protective benefit of the FOXO3 G-allele. Conversely, mTOR rs2295080 G-allele carriers already have lower mTOR expression; if AKT signaling is also elevated via rs3803304 GG, the net mTOR effect is unclear since AKT feeds into mTOR through TSC2. These combined PI3K-AKT-mTOR pathway interactions are biologically compelling but have not been formally tested in combined genotype studies. The Pawlikowska paper screened the full insulin/IGF1 axis and identified AKT1 and FOXO3A as the top signals, suggesting they tag partially independent longevity mechanisms within the same pathway.

Your skeleton is in a constant state of renovation. Every day, old bone is broken down by osteoclasts and replaced by new bone laid down by osteoblasts. What governs this process? In large part, a signaling cascade called the Wnt pathway¹¹ Wnt pathway
a highly conserved cellular communication system controlling cell proliferation, differentiation, and survival. LRP5 (low-density lipoprotein receptor-related protein 5) sits at the entry point of this pathway, acting as a co-receptor that captures Wnt proteins and relays their "build bone" message into cells. The Val667Met variant — so named because it swaps a valine amino acid for methionine at protein position 667 — subtly alters how efficiently this receptor does its job.

This variant is rare globally: the A (methionine) allele appears in about 4.7% of people of European descent, is exceptionally rare in East Asians (<0.1%), and is somewhat enriched in Ashkenazi Jewish populations (~9%). Homozygous AA individuals are extremely uncommon (~0.2%), making most genetic impact observable in AG heterozygotes.

The Mechanism

The Val667Met substitution falls in exon 10 of LRP5²² exon 10 of LRP5
one of four beta-propeller domains that bind Wnt pathway inhibitors and regulate receptor activation. The methionine substitution alters the local protein conformation within this propeller region, modestly reducing LRP5's ability to transduce Wnt signals into osteoblasts. With less Wnt signaling, osteoblasts receive a weaker "build bone" message throughout development and adult remodeling.

A 2023 functional study by Fabre et al.³³ Fabre et al.
using both human patients carrying the variant and transgenic mice engineered to express Val667Met demonstrated multiple downstream consequences: primary osteoblasts from variant mice showed diminished alkaline phosphatase activity and reduced mineralization capacity; bone matrix exhibited a lower hydroxyproline/proline ratio indicating compromised collagen cross-linking; and lumbar and hip BMD Z-scores were reduced in carrier patients. The pathway effect also extended to retinal vasculature — two patients showed vascular tortuosity, mirroring findings in LRP5 loss-of-function conditions.

The Evidence

The clearest population evidence comes from large male cohorts. Grundberg et al. 2008⁴⁴ Grundberg et al. 2008
combined three Scandinavian cohorts totaling 3,800 men and found that carriers of the Met allele had 3% lower lumbar spine BMD compared to non-carriers (p<0.05). The Odense Androgen Study (Brixen et al. 2007)⁵⁵ Odense Androgen Study (Brixen et al. 2007)
783 Caucasian men aged 20-30 found that each additional A allele was associated with a −0.26 Z-score change at the femoral neck (p=0.04) specifically in non-sedentary men, suggesting the variant's effect is most visible when bone is under mechanical load.

A key discovery emerged from a Greek postmenopausal cohort (Stathopoulou et al. 2010)⁶⁶ Greek postmenopausal cohort (Stathopoulou et al. 2010)
578 women followed for spine BMD and calcium intake patterns: A allele carriers had significantly lower spine BMD overall (p=0.002), but this effect was entirely confined to women consuming less than 680 mg calcium per day (p=0.001). Among women with higher calcium intake, the genotype difference disappeared — a textbook gene-nutrient interaction (interaction p=0.016) that points directly to a modifiable intervention.

The Framingham Offspring Cohort (Kiel et al. 2007)⁷⁷ Framingham Offspring Cohort (Kiel et al. 2007)
1,797 individuals with detailed exercise and BMD tracking found rs4988321 associated with Ward's triangle BMD (p=0.02) in younger men, with each rare allele changing BMD by 3-5%, and proposed the variant modulates how bone responds to mechanical loading via Wnt signaling.

Not all studies find significant associations: a Tunisian postmenopausal cohort and a Turkish osteoporosis study found no significant effect, suggesting the variant's impact may be attenuated in non-European populations and may depend on background genetic architecture, physical activity patterns, and lifetime calcium intake.

Practical Actions

The gene-nutrient interaction with calcium is actionable: if you carry the A allele, achieving calcium intakes above the level at which the association disappears in studies (roughly 700–800 mg/day from food and supplements combined) may blunt the genotypic disadvantage. Vitamin D is essential for calcium absorption, so ensuring adequate vitamin D status compounds this benefit. A BMD baseline measurement gives you a concrete data point to track over time and guides decisions about loading exercise regimens.

Interactions

The companion LRP5 variant rs3736228 (A1330V) affects the same Wnt co-receptor at a different domain and has similar effects on BMD. Individuals carrying risk alleles at both rs4988321 (Val667Met) and rs3736228 (A1330V) may have additive reduction in Wnt signaling and correspondingly greater BMD reduction, though published combined-genotype data are limited. The two variants appear to act independently in the same biological pathway. Additionally, since LRP5 mediates bone response to calcium and vitamin D signaling indirectly (via osteoblast differentiation), VDR variants (rs2228570, rs4588) that reduce vitamin D receptor efficiency may compound the BMD impact — though no single published study addresses all three loci together.

Your heart muscle relies on millisecond-precise calcium pulses to contract and relax in perfect rhythm. The junctophilin-2 protein, encoded by JPH2, is the structural bridge that makes this possible — a molecular tether clamping the plasma membrane and sarcoplasmic reticulum together so that the electrical signal arriving at the cell surface is faithfully translated into a calcium surge inside the cell. rs587782951¹¹ rs587782951
This single-nucleotide variant at chromosome 20q13.12 replaces threonine-161 with lysine, subtly but consequentially altering this coupling machinery. The result is hypertrophic cardiomyopathy (HCM) — the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young people.

The Mechanism

The JPH2 protein contains eight MORN (membrane occupation and recognition nexus) motifs at its N-terminus that anchor it to the plasma membrane, and a C-terminal transmembrane domain that inserts into the sarcoplasmic reticulum²² sarcoplasmic reticulum
the cell's internal calcium store membrane. Between them, the joining region spans the narrow junctional gap between the two membranes, holding them ~10–15 nm apart — a distance perfectly calibrated for calcium channel coupling.

The Thr161Lys substitution falls in the joining region, replacing a neutral polar amino acid (threonine) with a positively charged lysine. Studies in patient-derived iPSC cardiomyocytes show this disrupts protein localization and calcium inactivation kinetics³³ disrupts protein localization and calcium inactivation kinetics, producing a slower time constant of calcium current decay. The consequence: the action potential lingers longer at each beat, calcium handling is dysregulated across millions of cardiomyocytes, and the myocardium hypertrophies — thickening its walls in an attempt to compensate for impaired pump efficiency. Early afterdepolarizations (EADs) arising from this prolonged repolarization create the substrate for lethal arrhythmias.

The Evidence

JPH2 was established as an HCM disease gene in 2007, when Landstrom et al. screened 388 unrelated HCM patients⁴⁴ Landstrom et al. screened 388 unrelated HCM patients
Landstrom AP et al. J Mol Cell Cardiol 2007 and identified three novel JPH2 missense mutations (S101R, Y141H, S165F) absent in 1,000 control alleles. Each mutation caused protein reorganization, disrupted calcium signaling, and increased cardiomyocyte size — establishing a direct causal chain.

The Thr161Lys variant specifically was characterized in a Finnish founder-effect setting. Vanninen et al. 2018⁵⁵ Vanninen et al. 2018
Vanninen SUM et al. PLoS One 2018;13(9):e0203422 followed 26 heterozygous carriers across 9 families and found penetrance of 71% by age 60 and 100% by age 80 — unusually high for a single-gene cardiac variant. Clinical features included left ventricular hypertrophy, third-degree AV block, and end-stage systolic heart failure in a subset of carriers; co-segregation confirmed in 6 of 9 families. This variant is classified as pathogenic in ClinVar (VCV000155800), supported by multiple independent submissions.

The mechanism was further characterized in iPSC-derived cardiomyocytes: Valtonen et al. 2023⁶⁶ Valtonen et al. 2023
Biomedicines 2023;11(6):1558 showed Thr161Lys cardiomyocytes display significantly enlarged cell bodies, disrupted sarcomeric organization, prolonged action potentials at 50% and 90% repolarization, and spontaneous phase-3 early afterdepolarizations — recapitulating the patient arrhythmia phenotype at the cellular level.

Across a broader JPH2 landscape, Parker et al. 2023⁷⁷ Parker et al. 2023
Trends Cardiovasc Med 2023;33(1):1-10 systematically reviewed 61 JPH2 variant carriers and found 47% developed HCM, 18% DCM, and 14% experienced arrhythmia or sudden cardiac death — underscoring the high clinical stakes of JPH2 pathogenic variants as a class.

Practical Implications

Heterozygous carriers of the Thr161Lys variant face near-certain lifetime risk of HCM. The high age-dependent penetrance means that a carrier who is asymptomatic in their 30s may not yet have developed disease, making regular surveillance essential. HCM in JPH2 carriers has a distinctive phenotype: left ventricular hypertrophy combined with risk of high-grade conduction block and arrhythmia, which distinguishes it from sarcomeric HCM caused by MYH7 or MYBPC3 mutations. Early identification enables lifestyle risk reduction (avoiding competitive sports), pharmacologic management of symptoms, and implantable cardioverter-defibrillator consideration in high-risk individuals.

First-degree relatives of a carrier have a 50% probability of inheriting the variant and require cascade genetic testing regardless of current symptoms.

Interactions

JPH2 does not have established interactions with other HCM-associated genes of the type seen with sarcomeric compound heterozygosity (e.g. MYBPC3 + MYH7). However, disease expression may be modulated by variants in genes that regulate calcium handling, including RYR2 (ryanodine receptor) and CASQ2 (calsequestrin), which together with JPH2 form the junctional calcium signaling complex. These interactions are mechanistically plausible but not yet characterized in carriers of Thr161Lys specifically.

The BCO1 gene encodes beta-carotene 15,15'-monooxygenase¹¹ beta-carotene 15,15'-monooxygenase
The enzyme that cleaves one molecule of dietary beta-carotene into two molecules of retinal, which is subsequently reduced to retinol — the biologically active form of vitamin A, the single enzyme responsible for converting plant-derived provitamin A into a form the body can use. Most of the genetic variation in beta-carotene conversion has been attributed to two coding variants in BCO1 — rs7501331 (Ala379Val)²² rs7501331 (Ala379Val)
Reduces enzyme catalytic efficiency by ~32%; T allele frequency ~24% in Europeans and rs12934922 (Arg267Ser)³³ rs12934922 (Arg267Ser)
Reduces conversion by up to 69% when combined with Ala379Val; T allele frequency ~44% in Europeans — but these are not the full story.

The rs6420424 variant lies approximately 30 kilobases upstream of the BCO1 transcription start site, within the PKD1L2⁴⁴ PKD1L2
Polycystin 1 Like 2 — a gene encoding a membrane protein; rs6420424 is located in its sequence but functions as a regulatory element influencing BCO1 expression in the same chromosomal neighborhood gene region on chromosome 16. It acts not by changing the BCO1 protein sequence, but by modulating how much BCO1 enzyme is made. The A allele is associated with reduced BCO1 catalytic activity, reducing the rate at which beta-carotene is cleaved and converted to retinal.

The Mechanism

Unlike missense variants that alter the enzyme's amino acid sequence, rs6420424 is a regulatory variant⁵⁵ regulatory variant
A non-coding variant that changes the binding of transcription factors, enhancer activity, or chromatin accessibility, altering how much of a nearby protein-coding gene is expressed. Its position ~30 kb upstream of BCO1's first exon places it in a region that likely contains cis-regulatory elements⁶⁶ cis-regulatory elements
DNA sequences that control transcription of nearby genes, including enhancers, silencers, and transcription factor binding sites, acting in the same chromosome copy influencing BCO1 transcription in intestinal enterocytes, where most beta-carotene conversion takes place.

The rs6564851 variant, another upstream regulatory SNP located approximately 22 kb downstream of rs6420424 (at chr16:81,230,991), also reduces BCO1 activity — by ~48%. The two SNPs are in the same genomic neighborhood and were both identified by Lietz et al. 2012⁷⁷ Lietz et al. 2012
Lietz G et al. SNPs upstream from the beta-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency. J Nutr, 2012 as independently contributing to conversion efficiency, with rs6420424 showing a positive correlation (r=0.53, P=0.004) between the G allele and the retinyl palmitate:beta-carotene conversion ratio. A allele carriers have a lower ratio — meaning less beta-carotene is converted to retinol after a dietary dose.

The Evidence

The foundational characterization of this variant comes from Lietz and colleagues (2012)⁸⁸ Lietz and colleagues (2012)
Lietz G et al. SNPs upstream from the beta-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr, 2012, who measured the TG-rich lipoprotein retinyl palmitate:beta-carotene ratio in female volunteers following a controlled beta-carotene dose. Among three upstream regulatory SNPs tested (rs6420424, rs11645428, rs6564851), rs6420424 showed the largest effect — a 59% reduction in catalytic activity for A allele carriers. The study also documented large inter-ethnic variation in allele frequencies (43-84% for the A allele across populations), with East Asian populations carrying the A allele at particularly high frequency.

Supporting evidence comes from Feigl et al. (2014)⁹⁹ Feigl et al. (2014)
Feigl B et al. The relationship between BCMO1 gene variants and macular pigment optical density in persons with and without AMD. PLoS One, 2014, who examined BCO1 variants in relation to macular pigment optical density (MPOD) — a physiological measure of carotenoid accumulation in the eye. Healthy participants with the AA genotype at rs6420424 had significantly lower MPOD than GG carriers (P<0.01), consistent with reduced carotenoid delivery to the macula from impaired conversion of dietary precursors. The study identified a "high-conversion" genotype pattern (GG at rs6420424 / AA at rs11645428 / TT at rs6564851) with notably higher MPOD, confirming the biological relevance of this variant.

A 2024 population study by Von Holle et al.¹⁰¹⁰ Von Holle et al.
Von Holle A et al. Association between rs6564851 and rs6420424, and lutein/zeaxanthin levels in US postmenopausal women. Front Nutr, 2024 in 519 postmenopausal women found the A allele of rs6420424 inversely associated with circulating lutein/zeaxanthin levels (beta=-0.334, se=0.059, P=2.2×10⁻⁸), a significant genome-wide association replicated independently of rs6564851, which had its own distinct effect (beta=-0.377, P=4.6×10⁻¹⁰). This independent reporting in the same study provides the clearest available evidence that rs6420424 and rs6564851 have separable, non-redundant effects on carotenoid levels — though the formal LD structure between them requires further characterization.

Practical Implications

The clinical relevance of rs6420424 is greatest for people who depend on plant foods as their primary vitamin A source. For a person eating a typical Western mixed diet that includes eggs, dairy, and some meat, reduced BCO1 expression from this regulatory variant is largely compensated by preformed retinol from animal sources, which bypass BCO1 entirely.

The situation changes meaningfully for: - Vegans and vegetarians who derive essentially all vitamin A from beta-carotene in plant foods - People who also carry one or two T alleles at the BCO1 coding variants rs7501331 or rs12934922, creating a cumulative multi-variant poor converter phenotype - People in populations where plant-based provitamin A is the dietary vitamin A standard, particularly in sub-Saharan Africa and Southeast Asia — where this variant's population frequency also varies considerably

Plasma retinol testing is not sensitive for detecting suboptimal status; the liver buffers circulating retinol until stores are substantially depleted. Dietary diversity and preformed vitamin A sources are more practical levers than serum monitoring for mild variants like this one.

Interactions

The rs6420424 variant interacts additively with the other upstream regulatory variant rs6564851, which independently reduces BCO1 activity by 48%. Carriers of risk alleles at both loci are expected to have compounded reductions in BCO1 expression — though the combined effect has not been formally quantified in a single dose-response study.

More importantly, the regulatory variants compound with the BCO1 coding variants rs7501331 (Ala379Val) and rs12934922 (Arg267Ser), which reduce enzyme activity by 32% and contribute to the 69% reduction in compound carriers. An individual who carries risk alleles at both upstream regulatory variants and both coding variants could have substantially impaired beta-carotene conversion — well beyond any single variant's effect. Given the high A allele frequency of rs6420424 in East Asian populations (~86%), combined multi-variant poor converter profiles are likely common in those ancestry groups.

Herpes zoster — shingles — is not a new infection. It is varicella-zoster virus (VZV) waking up after decades of dormancy in your dorsal root ganglia, the nerve cell clusters flanking your spinal cord. Almost everyone who had chickenpox as a child carries the virus for life. Whether it stays dormant or breaks through depends critically on how well your immune system — and specifically your type I interferon¹¹ type I interferon
A family of cytokines (IFN-alpha and IFN-beta) released within hours of viral detection; they trigger antiviral gene expression in neighboring cells, resist viral replication, and prime adaptive immune responses response — patrols the territory. rs7047299 sits upstream of IFNA21, one of thirteen interferon alpha genes clustered on chromosome 9p21.3, and the A allele at this position is associated with greater susceptibility to shingles.

The Mechanism

IFNA21 encodes interferon alpha-21²² interferon alpha-21
One of 13 IFNA genes clustered on chromosome 9p21.3 encoding subtly distinct IFN-alpha protein isoforms with overlapping but non-identical antiviral potencies; the cluster evolved through repeated gene duplications, a type I interferon secreted primarily by plasmacytoid dendritic cells within hours of detecting viral DNA via TLR9 and other innate sensors. rs7047299 lies approximately 800 bp upstream of the IFNA21 transcription start site — within the proximal promoter/regulatory region — and is annotated as a 2 KB upstream regulatory variant.

Two independent lines of experimental work establish why this matters specifically for VZV. First, IFN-alpha from epidermal cells is the primary barrier to VZV skin spread³³ IFN-alpha from epidermal cells is the primary barrier to VZV skin spread
Blocking IFN-alpha receptor in ex vivo human skin increased VZV viral titers approximately tenfold; VZV itself down-regulates IFN-alpha in infected cells to enable focal replication while neighboring uninfected cells still mount a response. Second, IFN-alpha signals through the IFN-α–IRF9 axis⁴⁴ IFN-alpha signals through the IFN-α–IRF9 axis
IRF9 is an interferon regulatory factor induced by IFN-alpha signaling; it forms the ISGF3 transcription complex that activates hundreds of interferon-stimulated genes; VZV's IE62 protein transcriptionally suppresses IRF9 to escape this response as the first-line delay mechanism against VZV replication. A regulatory variant that reduces IFNA21 promoter activity — or alters expression timing — would blunt this initial barrier, giving the virus an earlier window to replicate before adaptive T cell immunity is mobilized.

The Evidence

The primary association comes from a [large multi-infection GWAS | 23 GWAS studies across

200,000 individuals of European ancestry tested for 23 common infections simultaneously; 59 genome-wide significant loci identified; designed to identify immune-genetic contributions using 23andMe participant cohort data](https://pubmed.ncbi.nlm.nih.gov/28928442/⁵⁵ https://pubmed.ncbi.nlm.nih.gov/28928442/) by Tian et al. (2017), which identified rs7047299 as a genome-wide significant hit for shingles susceptibility (OR = 1.07; 95% CI, 1.06–1.09; p = 2 × 10⁻⁸). The variant maps to the IFNA21/IFNWP15 chromosomal region, and the biological link to interferon-alpha production is mechanistically coherent. The per-allele OR of 1.07 is modest — comparable to many common GWAS risk alleles — but the genome-wide significance threshold provides high confidence that the association is real, not a false positive.

Complementary human evidence comes from patients with autoimmune polyendocrine syndrome type 1 (APS-1)⁶⁶ patients with autoimmune polyendocrine syndrome type 1 (APS-1)
APS-1 patients produce high-titer neutralizing autoantibodies against IFN-alpha; this natural human experiment allows researchers to observe the effect of IFN-alpha deficiency on infection susceptibility in a live clinical setting, who produce neutralizing autoantibodies against IFN-alpha and experience significantly higher rates of VZV reactivation — directly confirming that inadequate IFN-alpha signaling is sufficient to allow VZV to break through. These patients also show decreased humoral responses to VZV specifically, pointing to IFN-alpha's role in coordinating both innate and adaptive antiviral defenses.

The evidence level is moderate: the GWAS association is large-scale and genome-wide significant, the biological mechanism is experimentally established, but the specific functional impact of rs7047299 on IFNA21 expression has not been characterized in an eQTL study, and dose-response data for AA vs. AG vs. GG carriers are not available from the 2017 paper.

Practical Actions

The most directly actionable implication of carrying one or two copies of the A allele is that your innate antiviral response to VZV reactivation may be somewhat blunted — not absent, but operating at reduced efficiency. Shingrix (recombinant zoster vaccine, RZV) is specifically designed to compensate for this by building strong T cell memory against VZV glycoprotein E with its AS01B adjuvant system, achieving [≥90% efficacy against herpes zoster | ZOE-70 trial:

90% efficacy in adults 70+; ZOE-50 trial: 97.2% efficacy in adults 50–69; pooled long-term data show efficacy remains high at 10+ years post-vaccination](https://pubmed.ncbi.nlm.nih.gov/27626517/⁷⁷ https://pubmed.ncbi.nlm.nih.gov/27626517/) even when innate immune responses decline with age. Prioritizing Shingrix vaccination at the earliest eligible age (50 in most guidelines) is the highest-yield intervention.

Beyond vaccination, supporting robust IFN-alpha production involves avoiding immunosuppressive medications that explicitly block interferon signaling (JAK inhibitors, high-dose corticosteroids) when alternatives exist, and discussing shingles prophylaxis with your physician before starting any such treatments.

Interactions

The IFNA gene cluster on 9p21.3 contains thirteen IFNA genes in close proximity. Variants in neighboring interferon genes — particularly those affecting the broader interferon locus haplotype — may compound or buffer the effect of rs7047299. The IFNL3/IFNL4 locus on chromosome 19 (rs11322783, rs12979860) encodes type III interferons (lambda interferons) that act through a parallel pathway targeting epithelial cells; individuals with reduced type III interferon function alongside reduced type I interferon from rs7047299 may have broader antiviral vulnerability. Compound actions for this combination have not been studied, but the convergence of reduced innate signaling across multiple interferon families represents a biologically plausible interaction.

The APOL1 gene encodes apolipoprotein L1¹¹ apolipoprotein L1
a component of HDL particles that functions as the human innate immune system's weapon against African trypanosomes. APOL1 protein forms ion channels in the trypanosome membrane, killing the parasite. But Trypanosoma brucei rhodesiense evolved a countermeasure — the serum resistance-associated (SRA) protein²² serum resistance-associated (SRA) protein
binds to wild-type APOL1 and neutralizes it, allowing the parasite to survive in human blood.

The G2 variant (rs71785313) is a 6-base-pair in-frame deletion³³ 6-base-pair in-frame deletion
c.1164_1169del, removing asparagine-388 and tyrosine-389 in the C-terminal domain of APOL1. This deletion alters the SRA-binding site, preventing the trypanosome's defense protein from neutralizing APOL1. The result: carriers of even one G2 allele can kill T. b. rhodesiense⁴⁴ carriers of even one G2 allele can kill T. b. rhodesiense
five-fold dominant protective association against infection. This is the evolutionary advantage that drove G2 to high frequency in sub-Saharan Africa over the past 5,000-10,000 years.

The trade-off is kidney disease. In the homozygous state (G2/G2) or compound heterozygous with G1 (G1/G2)⁵⁵ homozygous state (G2/G2) or compound heterozygous with G1 (G1/G2)
a recessive model where two risk alleles are required, the altered APOL1 protein becomes toxic to kidney podocytes — the specialized cells that form the filtration barrier. This toxicity drives focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN), and hypertension-attributed end-stage kidney disease at dramatically elevated rates. The pattern mirrors sickle cell trait: one copy protects against a parasite, two copies cause disease.

The Mechanism

APOL1 is expressed in kidney podocytes, vascular endothelium, and circulating HDL particles⁶⁶ kidney podocytes, vascular endothelium, and circulating HDL particles
with highest expression in the kidney. The G2 deletion removes two amino acids from the C-terminal domain that normally interacts with the SRA protein of trypanosomes. While this disruption is beneficial for parasite killing, the altered protein also gains cytotoxic properties in kidney cells⁷⁷ cytotoxic properties in kidney cells
depleting cellular potassium and activating stress-activated protein kinases (SAPK/JNK).

In podocytes, the G2 variant forms aberrant ion channels in cell membranes and mitochondria⁸⁸ aberrant ion channels in cell membranes and mitochondria
opening the mitochondrial permeability transition pore and inducing cell death. Podocyte loss is irreversible — these cells do not regenerate — and progressive podocyte depletion leads to proteinuria, glomerulosclerosis, and eventual kidney failure. The disease requires a "second hit" (infection, inflammation, interferon signaling) to manifest, which explains why only 15-20% of individuals with two risk alleles develop kidney disease⁹⁹ 15-20% of individuals with two risk alleles develop kidney disease
the remaining ~80% never progress.

The Evidence

The landmark discovery by Genovese et al. (2010) in Science¹⁰¹⁰ landmark discovery by Genovese et al. (2010) in Science
mapping APOL1 risk variants after decades of attributing the association to nearby MYH9 identified G1 and G2 as the true causal variants for kidney disease disparities in African Americans. The original study found odds ratios of 10.5 for FSGS and 7.3 for hypertension-attributed ESKD in those with two risk alleles.

Kopp et al. (2011)¹¹¹¹ Kopp et al. (2011)
JASN study of 271 African American cases and 939 controls refined the risk estimates: OR=17 for FSGS, OR=29 for HIVAN, with APOL1-associated FSGS showing earlier age of onset and faster progression to ESKD. The recessive model was confirmed — heterozygous carriers showed no significant kidney disease risk.

The AASK/CRIC analysis by Parsa et al. (2013) in the New England Journal of Medicine¹²¹² AASK/CRIC analysis by Parsa et al. (2013) in the New England Journal of Medicine
693 Black patients with hypertensive CKD in AASK and 2,955 patients in CRIC demonstrated that APOL1 high-risk genotype accelerated CKD progression with a hazard ratio of 1.88 (P<0.001) for the composite endpoint of ESKD or doubling of serum creatinine. The effect was present regardless of diabetes status.

A breakthrough in treatment came with inaxaplin (VX-147)¹³¹³ inaxaplin (VX-147)
a small molecule that directly inhibits APOL1 channel function. The Phase 2a trial in 13 patients with two APOL1 risk variants and biopsy-proven FSGS showed a 47.6% mean reduction in proteinuria at 13 weeks, providing the first genotype-targeted therapy for APOL1 nephropathy.

Practical Actions

APOL1 G2 kidney risk follows a recessive pattern — one copy confers trypanosome protection with minimal kidney risk, while two copies (G2/G2 or G1/G2 compound heterozygous) create significant kidney disease susceptibility. If you carry two risk alleles, proactive monitoring is essential because early detection dramatically improves outcomes.

The key biomarkers are urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)¹⁴¹⁴ urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)
early proteinuria and declining filtration are the first signs of APOL1 nephropathy. Annual screening can catch disease years before symptoms appear. Blood pressure control is critical — hypertension accelerates podocyte loss in APOL1 high-risk kidneys.

For those with two risk alleles considering kidney donation, APOL1 genotyping is now recommended before living donation, as donors with high-risk genotypes face accelerated post-donation kidney function decline.

Interactions

APOL1 G2 and G1 (rs73885319 + rs60910145)¹⁵¹⁵ G1 (rs73885319 + rs60910145)
the other APOL1 risk haplotype comprising S342G and I384M missense variants interact through compound heterozygosity. G1/G2 compound heterozygotes carry the same kidney disease risk as G1/G1 or G2/G2 homozygotes — any combination of two risk alleles activates the recessive disease mechanism.

The recently discovered APOL1 p.N264K variant¹⁶¹⁶ APOL1 p.N264K variant
a missense change in the pore-lining domain acts as a powerful modifier. When inherited in cis with G2 (on the same chromosome), N264K abolishes the cytotoxic effect, strongly protecting against FSGS and kidney disease even in compound heterozygotes. This modifier is co-inherited with G2 through a proximity recombination event and explains some of the incomplete penetrance.

HIV infection is a critical environmental modifier — HIVAN occurs almost exclusively in individuals with two APOL1 risk alleles¹⁷¹⁷ HIVAN occurs almost exclusively in individuals with two APOL1 risk alleles
OR=29 for HIVAN vs. controls. Interferon signaling upregulates APOL1 expression, and the amplified production of toxic G2 protein in podocytes drives rapid kidney destruction. Effective antiretroviral therapy substantially reduces but does not eliminate this risk.

Proposed compound actions for supervisor review:

1. APOL1 G2/G2 homozygous (rs71785313 DD)

• Genotypes: rs71785313 DD
• Combined effect: Two copies of G2 deletion — high-risk genotype for APOL1 nephropathy
• Evidence: OR=10-17 for FSGS, OR=29 for HIVAN, HR=1.88 for CKD progression
• Recommendation: Annual UACR + eGFR screening, strict BP control <130/80, nephrology referral if proteinuria detected, discuss inaxaplin eligibility
• Note: This is a single-genotype action, not compound — included here for visibility

2. APOL1 G1/G2 compound heterozygous

• Genotypes: rs73885319 (G1 component, if added to system) + rs71785313 DI
• Combined effect: Same high-risk phenotype as G2/G2 homozygous — any two APOL1 risk alleles
• Evidence: Identical ORs to homozygous risk genotypes (Genovese 2010, Kopp 2011)
• Recommendation: Same as G2/G2 — annual screening, BP control, nephrology awareness
• Note: Requires G1 SNPs (rs73885319, rs60910145) to be added to system first

Glaucoma is the leading cause of irreversible blindness worldwide, affecting over 80 million people. Most cases are "open-angle" — the drainage angle of the eye looks normal under examination, yet fluid builds up and silently crushes the optic nerve over years. For a small but well-defined group of patients, the culprit is a single-letter change in the MYOC gene¹¹ MYOC gene
MYOC (myocilin) encodes a glycoprotein secreted into the aqueous humor of the eye. Originally discovered as the trabecular meshwork-induced glucocorticoid response protein (TIGR), MYOC is highly expressed in the trabecular meshwork — the sponge-like tissue responsible for draining aqueous humor from the eye and regulating intraocular pressure. The Gln368Ter variant — also written Q368X or p.Gln368Ter — introduces a premature stop codon that truncates the myocilin protein at position 368, making it the most frequently identified single-gene cause of open-angle glaucoma in populations of European descent.

This variant is classified Pathogenic by ClinVar²² Pathogenic by ClinVar
ClinVar variation VCV000007949; reviewed by the ClinGen Glaucoma Variant Curation Expert Panel in January 2026 and awarded four stars — the highest review tier, signifying consensus among an independent panel of glaucoma genetics experts and listed as OMIM allelic variant 601652.0003. Unlike many "risk variants" that confer modest statistical elevation in population studies, Q368X reliably causes disease in the families in which it segregates — though its penetrance is incomplete and age-dependent.

The Mechanism

Myocilin is secreted into the aqueous humor and extracellular matrix of the trabecular meshwork, where it participates in maintaining the tissue architecture that regulates aqueous drainage. The Gln368Ter substitution (c.1102C>T in coding sequence; G>A at the plus-strand chromosomal level) introduces a premature stop codon at position 368, truncating the olfactomedin domain — the C-terminal functional region of the protein.

The critical insight is that truncated myocilin is not simply absent — it is retained inside the cell³³ truncated myocilin is not simply absent — it is retained inside the cell
Studies show that mutant myocilin including Q368X accumulates in the endoplasmic reticulum rather than being properly secreted. This ER retention triggers unfolded protein response (UPR) stress and, over time, trabecular meshwork cell death. Mutant myocilin also activates the IL-1/NF-κB inflammatory pathway in trabecular meshwork cells — stimulating release of IL-1α and IL-1β — while wild-type myocilin normally suppresses this inflammatory cascade. The consequence is progressive trabecular meshwork dysfunction, impaired aqueous outflow, and chronically elevated intraocular pressure (IOP) that damages the optic nerve.

Because MYOC is also expressed in vascular endothelial cells and smooth muscle, dysfunction in myocilin may affect shared vascular regulatory pathways. The trabecular meshwork itself is a specialized vascular endothelial structure, and the vascular mechanisms maintaining IOP homeostasis overlap with systemic endothelial biology — providing a rationale for tracking this variant in the cardiovascular context of its heart-inflammation category.

The Evidence

The evidence for Q368X as a cause of open-angle glaucoma is among the strongest in ophthalmic genetics.

Cheng et al., 2012⁴⁴ Cheng et al., 2012
Cheng JW et al. Myocilin polymorphisms and primary open-angle glaucoma: a systematic review and meta-analysis. PLoS One 7(11):e50inner, 2012 — 32 case-control studies meta-analysed 32 case-control studies and found Q368X associated with POAG at an odds ratio of 4.68 (95% CI 2.02–10.85), rising to 5.17 in Western populations (95% CI 2.16–12.40). The association is stronger for high-tension glaucoma (OR 4.26), consistent with the IOP-elevating mechanism.

At the population level, MYOC mutations account for 3–5% of adult-onset POAG and 10–33% of juvenile-onset open-angle glaucoma (JOAG)⁵⁵ juvenile-onset open-angle glaucoma (JOAG)
JOAG is defined as POAG with onset before age 40. It typically presents with much higher IOP (often >30 mmHg) than adult-onset POAG and frequently requires surgical intervention. MYOC mutations are far more prevalent in JOAG than in late-onset POAG. Q368X is the single most prevalent MYOC disease-causing mutation in European- ancestry populations.

The ClinGen Glaucoma Variant Curation Expert Panel's January 2026 review awarded Q368X the highest ClinVar review tier (4 stars, Pathogenic), reflecting segregation data from multiple affected families, the damaging nature of the stop-gain alteration, and functional evidence from trabecular meshwork cell studies.

Itakura et al., 2015⁶⁶ Itakura et al., 2015
Itakura T, Peters DM, Fini ME. Glaucomatous MYOC mutations activate the IL-1/NF-kappaB inflammatory stress response and the glaucoma marker SELE in trabecular meshwork cells. Mol Vis 21:1071–84, 2015 demonstrated that Q368X and other glaucoma-causing MYOC mutants robustly activate the IL-1/NF-κB axis — providing a mechanistic bridge between the genetic lesion and trabecular meshwork pathology.

Practical Actions

Identifying a Q368X carrier fundamentally changes ophthalmologic management: annual IOP measurement and optic nerve assessment is the cornerstone, since early detection of elevated IOP (before optic nerve damage) is the window where treatment is most effective. IOP-lowering therapy (topical prostaglandin analogues, beta-blockers, or surgical procedures such as trabeculectomy or minimally invasive glaucoma surgery) can halt progression if started before significant nerve fiber loss occurs. Carriers should inform first-degree relatives, each of whom has a 50% chance of inheriting this autosomal dominant variant.

Carriers should be counseled that penetrance is incomplete — not all Q368X carriers will develop clinical glaucoma, and age of onset varies widely — but the risk is high enough to justify lifelong ophthalmologic surveillance beginning in the second decade of life.

Interactions

MYOC Q368X interacts functionally with other glaucoma risk variants. Digenic inheritance has been described in MYOC: Q368X combined with variants in CYP1B1 (an enzyme involved in ocular metabolism) appears in some families with more severe early-onset glaucoma than expected from Q368X alone. Additionally, MYOC Gly399Val/Asp (rs28936694, the variant originally specified in this research brief) is a related MYOC missense variant at the adjacent codon 399 and has also been associated with digenic glaucoma. These interactions suggest that the MYOC olfactomedin domain is a hotspot for dominant glaucoma mutations, and compound carriers warrant closer surveillance.

On chromosome 15, a busy stretch of DNA called 15q25.1 houses a cluster of nicotinic acetylcholine receptor genes — CHRNA5, CHRNA3, and CHRNB4 — plus several neighboring genes including AGPHD1 (also known as HYKK, hydroxylysine kinase). The rs8034191 variant sits in the third intron of AGPHD1, just upstream of the CHRNA3 gene that codes for the alpha-3 nicotinic receptor subunit. This locus has been among the most replicated findings in lung cancer and nicotine dependence genomics¹¹ This locus has been among the most replicated findings in lung cancer and nicotine dependence genomics
Multiple GWAS identified chromosome 15q25 variants at p-values below 10⁻¹⁸ for lung cancer, and rs8034191 is one of two key tagging variants at this region — the other being rs1051730 in CHRNA3, which is already covered in GeneOps.

Although rs8034191 and rs1051730 are in high linkage disequilibrium (r²=0.91 in Europeans), they are not identical and are partially independent in non-European populations. Understanding rs8034191 adds meaningful information for people of African or Asian ancestry, where the LD structure differs, and helps characterize the regulatory — rather than coding — mechanisms at this locus.

The Mechanism

Unlike rs1051730, which is a synonymous coding change in CHRNA3, rs8034191 is a non-coding intronic variant. Its functional impact operates through gene regulation: rs8034191 acts as a lung cis- and trans-eQTL²² rs8034191 acts as a lung cis- and trans-eQTL
Expression quantitative trait loci alter how much mRNA a gene produces in specific tissues, influencing the expression of multiple nearby genes including CHRNA3, CHRNA5, HYKK, IREB2, and PSMA4 in lung tissue. The C allele is associated with altered expression of these genes independently of smoking status, meaning the regulatory effect is present regardless of tobacco exposure.

The variant also influences [DNA methylation patterns | Epigenetic modification of cytosine bases that silences or activates gene regions] at the IREB2, CHRNA3, and PSMA4 promoters, independently of smoking. IREB2 encodes iron-regulatory protein 2 and has been implicated in COPD pathogenesis. The combined eQTL and methylation effects suggest rs8034191 reshapes the entire transcriptional landscape of this genomic neighborhood.

Approximately 30% of the variant's effect on COPD development is mediated through smoking behavior (pack-years), while the remaining effect is direct — acting through the gene expression changes described above. This distinguishes rs8034191 from a purely behavioral risk factor.

The Evidence

A 14-study meta-analysis³³ 14-study meta-analysis
Covering 14,075 cases and 12,873 controls from published case-control studies found that the C allele confers OR=1.23 (95% CI: 1.08–1.40; P=0.002) for lung cancer under the allelic model. The effect is strongest in Caucasians (OR=1.22) and African Americans (OR=1.39) and absent in East Asians, where the C allele is rare (frequency ~3%).

A separate 13-study meta-analysis⁴⁴ 13-study meta-analysis
Testing three genetic models — dominant, additive, and recessive confirmed significant associations across all three models: dominant OR=1.34 (95% CI: 1.29–1.41), additive OR=1.61 (95% CI: 1.50–1.73), and recessive OR=1.41 (95% CI: 1.32–1.50). The recessive model finding — indicating that two copies of the C allele confer a disproportionate effect — is a distinctive feature of rs8034191 compared to rs1051730.

For COPD, a genome-wide association study of COPD⁵⁵ genome-wide association study of COPD
Bergen et al., PLOS Genetics 2009, including subjects from multiple cohorts found rs8034191 significantly associated with COPD (OR=1.29, 95% CI: 1.18–1.41), with the population attributable risk of the C allele estimated at 12.2% for COPD in the general population and 14.3% in current smokers. An independent mediation analysis found that 30% of the COPD effect is mediated by smoking behavior⁶⁶ 30% of the COPD effect is mediated by smoking behavior
Measured as pack-years in path analysis models, meaning 70% operates through direct biological mechanisms.

For smoking behavior, a Canadian cohort study⁷⁷ a Canadian cohort study
526 women in Northeastern Ontario found that women carrying the CC genotype had a 2.8-fold increased odds of being heavy smokers (>20 cigarettes/day) after adjusting for age, confirming the variant's strong influence on smoking quantity independent of other factors. The variant is also associated with nicotine and opioid dependence severity, demonstrating a pleiotropic role across addictive substances⁸⁸ demonstrating a pleiotropic role across addictive substances
The same nicotinic receptor locus influences dependence on multiple drugs via overlapping neural circuits.

Practical Implications

If you carry one or two copies of the C allele, your baseline risk for heavy nicotine dependence and lung disease is elevated through both behavioral and biological pathways. The behavioral pathway: C allele carriers experience altered nicotinic receptor activity, making them more vulnerable to progressing from occasional to heavy smoking. The biological pathway: even independent of smoking, the eQTL effects on CHRNA3 and IREB2 expression appear to influence lung tissue susceptibility.

For smokers, the priority is cessation — the evidence consistently shows that quitting reduces lung cancer and COPD risk substantially regardless of genotype. For CC carriers who have never smoked, the direct biological effect (30% of the COPD risk) is still present but substantially lower in absolute terms than for smokers. Lung function monitoring is warranted for CC smokers, particularly spirometry to detect early obstructive patterns.

The variant is particularly relevant for people of African ancestry, where the LD structure between rs8034191 and rs1051730 is weaker, and the two variants provide partially independent information about risk.

Interactions

rs8034191 is in strong linkage disequilibrium with rs1051730 in CHRNA3 (r²=0.91 in Europeans), meaning most Europeans with the C allele also carry the rs1051730-A allele. In non-European populations, particularly African Americans, this correlation is weaker, making rs8034191 and rs1051730 partially independent risk indicators. The locus also contains rs16969968 in CHRNA5, which encodes the functionally impactful Asp398Asn amino acid change — rs16969968 is the strongest single functional variant at this locus, while rs8034191 captures primarily regulatory effects.

The three variants can be considered a risk haplotype: individuals who carry risk alleles at all three (rs16969968-A, rs1051730-A, rs8034191-C) are at substantially higher cumulative risk for nicotine dependence, lung cancer, and COPD than those carrying any single risk allele alone, though no published compound-genotype analyses exist to precisely quantify the triple-carrier odds ratio.

The melanocortin-4 receptor (MC4R) is the central satiety switch in the brain's hypothalamic energy balance circuit¹¹ hypothalamic energy balance circuit
the hypothalamus integrates signals from fat cells, gut hormones, and the brainstem to regulate hunger and energy expenditure. When the MC4R pathway is working, leptin from fat cells activates POMC neurons that release alpha-melanocyte stimulating hormone (α-MSH), which binds MC4R receptors and sends "stop eating" signals. The rs8087522 variant sits approximately 2 kilobases upstream of the MC4R gene — in the regulatory DNA that controls how much MC4R the hypothalamus produces.

This is a depth variant. The GeneOps platform already covers rs17782313²² rs17782313
the primary MC4R-region obesity GWAS signal, 188kb downstream of MC4R, which has a robust obesity association replicated in tens of thousands of participants. rs8087522 sits directly upstream of MC4R's coding sequence and tags a different aspect of MC4R regulation. Its specific clinical relevance has emerged primarily in the context of medication-induced weight gain rather than general obesity.

The Mechanism

rs8087522 is a G-to-A substitution at position 60,373,245 on chromosome 18 (GRCh38), approximately 2kb upstream of the MC4R transcription start site. MC4R itself is encoded on the minus strand, but rs8087522 alleles are reported in plus-strand orientation (G=reference, A=alternate).

In vitro electrophoretic mobility-shift assay³³ In vitro electrophoretic mobility-shift assay
EMSA: a technique where protein extracts are incubated with labeled DNA to detect transcription factor binding data from one pharmacogenomics study suggest that the A allele may create a transcription factor binding site absent in the G allele. If confirmed, this would give the A allele the capacity to alter MC4R upstream regulatory activity — potentially changing how much receptor protein is expressed in hypothalamic neurons. However, this functional evidence is limited to a single in vitro assay and has not been replicated in human brain tissue or animal models.

The nearby rs489693⁴⁴ rs489693
a variant ~158kb upstream of rs8087522 on chromosome 18, mapped near the MC4R region in GWAS studies has been independently associated with antipsychotic-induced weight gain at genome-wide significance (P=5.59×10⁻¹²), confirming that the MC4R upstream regulatory region as a whole influences medication-related energy dysregulation.

The Evidence

Direct evidence for rs8087522 is sparse and should be read honestly:

General obesity: Two studies have directly tested rs8087522 for obesity association and found none. Beckers et al. (2011)⁵⁵ Beckers et al. (2011)
association study of MC4R tagSNPs in 1,049 obese Belgian adults vs. 312 lean controls genotyped rs8087522 alongside rs17782313 and rs1943226 and found "no associations with obesity" for the upstream variants, while rs17782313 replicated strongly (OR=1.42, p=0.002). Yilmaz et al. (2015)⁶⁶ Yilmaz et al. (2015)
328 European ancestry individuals, five MC4R markers similarly found no independent rs8087522 signal for BMI or overeating behaviors.

Antipsychotic-induced weight gain: The most specific finding for rs8087522 comes from Chowdhury et al. (2012)⁷⁷ Chowdhury et al. (2012)
224 schizophrenia patients on antipsychotics, 14-week follow-up. European-ancestry patients carrying the A allele who were taking clozapine gained significantly more weight than non-carriers (P=0.027, n=69 in the clozapine subgroup). The authors caution that this association was marginal after correction for multiple testing and described the findings as exploratory, warranting further investigation. The proposed mechanism — A-allele creation of a transcription factor binding site (confirmed by EMSA) — adds biological plausibility, but the clinical signal remains unconfirmed.

The broader context for MC4R upstream variants in antipsychotic weight gain is stronger. The nearby rs489693 reached genome-wide significance in a multi-cohort study of 344 pediatric and adult patients (meta-analysis P=5.59×10⁻¹²), with minor allele homozygotes gaining substantially more weight on second-generation antipsychotics including clozapine, olanzapine, and quetiapine. The rs489693 finding has been independently replicated, making the MC4R upstream region a credible antipsychotic pharmacogenomics locus even if the specific contribution of rs8087522 within that region remains to be established.

Practical Implications

For individuals prescribed clozapine specifically, A-allele status at rs8087522 may be one element of a broader MC4R-region pharmacogenomic risk profile. Clozapine is disproportionately associated with weight gain among antipsychotics — average gain of 4-6 kg over the first year — and MC4R pathways are mechanistically implicated in how the drug suppresses hypothalamic satiety neurons. The A allele's potential to alter MC4R upstream regulation means that individuals carrying it on clozapine may warrant closer metabolic monitoring from the start of treatment.

For general weight management outside of antipsychotic use, the current evidence does not support rs8087522 as an independent risk factor. The primary MC4R-region signal for common obesity risk remains rs17782313, which has a well-established, large-cohort evidence base.

Interactions

rs17782313 (the primary MC4R-region obesity variant): rs17782313 is located 188kb downstream of MC4R in a separate regulatory block and has a robust, independent obesity association. rs8087522 sits in the proximal upstream region and has been tested in studies alongside rs17782313 — in those studies, the two variants do not show correlated effects on obesity. They likely tag different aspects of MC4R regulation and should be interpreted independently.

rs489693 (MC4R-region antipsychotic pharmacogenomics variant): rs489693 lies roughly 157kb from rs8087522 on chromosome 18 and has a strong, replicated association with antipsychotic-induced weight gain (genome-wide significance in multi-cohort GWAS). Both variants tag the MC4R regulatory region in the context of drug-induced weight gain, and their combined effect has not been formally studied. Individuals carrying risk alleles at both loci may face amplified antipsychotic weight gain risk, though this is speculative without published compound-genotype data.